Tarsus Secures $15 Million Milestone As China Approves TP-03 Eye Therapy Through Grand Pharma Partnership

Tarsus Pharmaceuticals has secured a $15 million milestone payment following regulatory approval of TP-03 (lotilaner ophthalmic solution) 0.25% in China. The therapy, marketed in the United States as XDEMVY®, received clearance from the National Medical Products Administration, marking a significant step in the product’s international expansion.

The approval was obtained by Grand Pharmaceutical Group Limited, Tarsus’ exclusive regional partner responsible for developing and commercialising TP-03 for Demodex blepharitis across Greater China, including mainland China, Hong Kong, Macau, and Taiwan. The decision enables commercialisation of the treatment in a major ophthalmology market with high unmet medical need.

“TP-03 is once again the first and only therapy approved to address the root cause of Demodex blepharitis, marking a meaningful advance for the more than 40 million people in the region affected by this disease,” said Bobak Azamian, M.D., PhD, Chief Executive Officer and Chairman of Tarsus. “This approval underscores our commitment to bringing this much-needed treatment to patients worldwide, and we look forward to supporting Grand Pharma as they prepare for launch.”

Under the partnership agreement, the milestone payment was triggered by both regulatory approval in China and the issuance of related patents, both of which have now been fulfilled. Tarsus remains eligible for additional payments tied to future regulatory achievements, sales-based milestones in China, and tiered royalties from product revenues generated across the Greater China territory.